1453070-07-9

Upstream product

• 1453069-66-3 (1S,8aS)-tert-butyl 7,7-diallyl-6-oxo-1-o-tolylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate 
• 1453069-65-2 (1S,8aS)-tert-butyl 6-oxo-1-o-tolylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate 
• 1453069-64-1 (1S,8aS)-1-o-tolylhexahydropyrrolo[1,2-a]pyrazin-6(7H)-one 
• 1453069-33-4 benzyl N-(2-{2-[(2-methylphenyl)carbonyl]-5-oxopyrrolidin-1-yl}ethyl)carbamate 
• 1453069-32-3 benzyl N-{2-[5-(2-methylphenyl)pent-4-ynamido]ethyl}carbamate 
• 1228573-50-9 N-[2-(benzyloxycarbonylamino)ethyl]pent-4-ynamide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1453069-67-4 (1S,8aS)-7,7-diallyl-1-o-tolylhexahydropyrrolo[1,2-a]pyrazine-6(7H)-one 
• 1453070-06-8 (R)-1-(3-methoxy-5-(trifluoromethyl)phenyl)-N-methylethanamine 
• 1453070-05-7 (S)-N-((R)-1-(3-methoxy-5-(trifluoromethyl)phenyl)ethyl)-N,2-dimethylpropane-2-sulfinamide 
• 1453070-04-6 (S)-N-((R)-1-(3-hydroxy-5-(trifluoromethyl)phenyl)ethyl)-N,2-dimethylpropane-2-sulfinamide 
• 1453070-03-5 (S)-N,2-dimethyl-N-((R)-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)phenyl)ethyl)propane-2-sulfinamide 
• 1453069-83-4 (S)-N-((R)-1-(3-bromo-5-(trifluoromethyl)phenyl)ethyl)-N,2-dimethylpropane-2-sulfinamide 
• 1453069-81-2 (S)-N-((R)-1-(3-bromo-5-(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide 

Downstream Products

• 1453069-04-9 (1S,8aS)-7,7-bis(2-hydroxyethyl)-N-((R)-1-(3-methoxy-5-(trifluoromethyl)phenyl)ethyl)-N-methyl-6-oxo-1-o-tolylhexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide 

Relevant academic research and scientific papers

NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS

The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hyd